- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04219254 | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 197 | BioInvent International ABINDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT05620472 | Molecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 |
| NCT07664397 | Imaging Study of [89Zr]DFO-YS5 for Cancer Detection | not yet recruiting | Phase 1 | 40 | Robert Flavell, MD, PhDOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06554795 | First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | DualityBio Inc.INDUSTRY | 3 | Jun 5, 2026 | clinicaltrials |
| NCT04621435 | Imaging of Solid Tumors Using FAP-2286 | recruiting | Phase 1 | 191 | Thomas HopeOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | recruiting | Phase 1 | 665 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06977737 | A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours(ATTEST) | recruiting | Phase 1 / Phase 2 | 72 | Accession Therapeutics LimitedINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT05678010 | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer | active not recruiting | Phase 1 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT03686124 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors(ACTengine) | recruiting | Phase 1 / Phase 2 | 375 | Immatics US, Inc.INDUSTRY | 2 | May 13, 2026 | clinicaltrials |
| NCT05036226 | COAST Therapy in Advanced Solid Tumors and Prostate Cancer(COAST) | recruiting | Phase 1 / Phase 2 | 76 | Medical University of South CarolinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05582850 | DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours(EPRAD) | terminated | Phase 1 | 29 | Domain Therapeutics SAINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT07159828 | A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 3 | Axion Bio, IncINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT05359445 | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor | active not recruiting | Phase 1 | 95 | Immatics Biotechnologies GmbHINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT01281176 | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06326411 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) | recruiting | Phase 1 | 230 | Nested Therapeutics, IncINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | terminated | Phase 1 | 17 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics(BHARAT-1) | terminated | Phase 1 | 27 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05071846 | MVX-ONCO-2 in Advanced Solid Tumors | active not recruiting | Phase 1 | 6 | University Hospital, GenevaOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03594422 | A Study of HQP1351 in Patients With GIST or Other Solid Tumors | recruiting | Phase 1 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors(STEALTH-001) | recruiting | Phase 1 | 60 | KaliVir ImmunotherapeuticsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05752552 | Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours | recruiting | Phase 1 | 55 | DeuterOncologyINDUSTRY | 3 | Apr 3, 2026 | clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT04143711 | Study of DF1001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 270 | Dragonfly TherapeuticsINDUSTRY | 6 | Mar 18, 2026 | clinicaltrials |
| NCT04443088 | An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors(KEYNOTE-E12) | recruiting | Phase 1 | 78 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05689853 | Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 87 | AkesoINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06108479 | Study of DF6215 in Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Dragonfly TherapeuticsINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06391918 | Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 37 | GenVivo, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07417189 | A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) | recruiting | Phase 1 / Phase 2 | 401 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors(MAST) | terminated | Phase 1 | 66 | Imugene LimitedINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT06063317 | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)(OASIS) | terminated | Phase 1 | 25 | Imugene LimitedINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05381909 | A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors | terminated | Phase 1 | 157 | BeiGeneINDUSTRY | 5 | Feb 20, 2026 | clinicaltrials |
| NCT04041310 | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 115 | Nouscom SRLINDUSTRY | 6 | Feb 13, 2026 | clinicaltrials |
| NCT03465592 | Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | recruiting | Phase 1 / Phase 2 | 39 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05276284 | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy(TEMPLE) | completed | Phase 1 / Phase 2 | 18 | Kristoffer RohrbergOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04587479 | A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 41 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | recruiting | Phase 1 / Phase 2 | 348 | Corbus Pharmaceuticals Inc.INDUSTRY | 7 | Jan 8, 2026 | clinicaltrials |
| NCT03905148 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | completed | Phase 1 | 91 | BeiGeneINDUSTRY | 2 | Jan 7, 2026 | clinicaltrials |
| NCT03573310 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | completed | Phase 1 | 114 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT05147272 | Study of RP-6306 With Gemcitabine in Advanced Solid Tumors | terminated | Phase 1 | 67 | Debiopharm International SAINDUSTRY | 3 | Dec 5, 2025 | clinicaltrials |
| NCT06439888 | Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer(LySATRA) | recruiting | Phase 1 / Phase 2 | 58 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 25, 2026source: clinicaltrials